Dafna Capital Management LLC Leap Therapeutics, Inc. Transaction History

Dafna Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$1.68 - $2.17 $462,000 - $596,750	-275,000 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $382,250 - $781,000	275,000 New	275,000 $575,000
Q1 2019 May 15, 2019	SELL	$1.39 - $3.07 $236,299 - $521,900	-170,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.92 - $7.94 $56,365 - $233,094	29,357 Added 20.87%	170,000 $340,000
Q3 2018 Nov 14, 2018	SELL	$6.52 - $9.13 $71,720 - $100,430	-11,000 Reduced 7.25%	140,643 $1.1 Million
Q2 2018 Aug 13, 2018	SELL	$6.76 - $10.01 $326,893 - $484,053	-48,357 Reduced 24.18%	151,643 $1.37 Million
Q1 2018 May 15, 2018	BUY	$6.06 - $8.54 $555,520 - $782,861	91,670 Added 84.62%	200,000 $1.66 Million
Q4 2017 Feb 14, 2018	BUY	$4.99 - $7.3 $540,566 - $790,809	108,330	108,330 $676,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.